Novo Nordisk A/S, SpringWorks Therapeutics, Apollo Global Management, Blackstone, and BlackRock are the five Growth stocks to watch today, according to MarketBeat's stock screener tool. Growth stocks are shares of companies whose earnings are expected to grow at an above-average rate compared to the overall market. These firms typically reinvest most of their profits back into the business rather than paying dividends, leading investors to value them based on future revenue and profit potential. While growth stocks can offer substantial upside if expansion targets are met, they also tend to be more volatile and carry greater risk if anticipated growth does not materialize. These companies had the highest dollar trading volume of any Growth stocks within the last several days.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of Novo Nordisk A/S stock traded up $1.38 on Wednesday, hitting $67.67. 8,894,343 shares of the company's stock traded hands, compared to its average volume of 6,267,121. The company has a market capitalization of $303.66 billion, a price-to-earnings ratio of 20.59, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The company has a fifty day moving average of $70.60 and a two-hundred day moving average of $87.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15.
Read Our Latest Research Report on NVO
SpringWorks Therapeutics (SWTX)
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.
SWTX traded up $0.05 during trading on Wednesday, hitting $46.21. The company's stock had a trading volume of 4,107,127 shares, compared to its average volume of 1,948,057. The firm has a market capitalization of $3.46 billion, a P/E ratio of -13.28 and a beta of 0.77. SpringWorks Therapeutics has a twelve month low of $28.21 and a twelve month high of $62.00. The stock's fifty day moving average price is $44.83 and its 200-day moving average price is $41.33.
Read Our Latest Research Report on SWTX
Apollo Global Management (APO)
Apollo Global Management, Inc. is a private equity firm specializing in investments in credit, private equity, infrastructure, secondaries and real estate markets. The firm prefers to invest in private and public markets. The firm's private equity investments include traditional buyouts, recapitalization, distressed buyouts and debt investments in real estate, corporate partner buyouts, distressed asset, corporate carve-outs, middle market, growth, venture capital, turnaround, bridge, corporate restructuring, special situation, acquisition, and industry consolidation transactions.
Shares of Apollo Global Management stock traded up $0.12 during trading on Wednesday, reaching $129.43. 1,402,652 shares of the company traded hands, compared to its average volume of 3,847,065. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.44 and a quick ratio of 1.44. The firm has a market capitalization of $73.84 billion, a PE ratio of 17.70, a P/E/G ratio of 1.17 and a beta of 1.67. The company has a 50 day moving average price of $132.55 and a 200-day moving average price of $152.80. Apollo Global Management has a 1-year low of $95.11 and a 1-year high of $189.49.
Read Our Latest Research Report on APO
Blackstone (BX)
Blackstone Inc. is an alternative asset management firm specializing in real estate, private equity, hedge fund solutions, credit, secondary funds of funds, public debt and equity and multi-asset class strategies. The firm typically invests in early-stage companies. It also provide capital markets services.
Shares of BX stock traded up $2.49 on Wednesday, reaching $136.49. 1,251,334 shares of the company were exchanged, compared to its average volume of 3,754,739. Blackstone has a one year low of $115.66 and a one year high of $200.96. The company has a market cap of $99.56 billion, a price-to-earnings ratio of 37.61, a PEG ratio of 1.07 and a beta of 1.67. The company has a 50-day moving average of $137.96 and a 200-day moving average of $162.87. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.67 and a quick ratio of 0.71.
Read Our Latest Research Report on BX
BlackRock (BLK)
BlackRock, Inc. is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors including corporate, public, union, and industry pension plans, insurance companies, third-party mutual funds, endowments, public institutions, governments, foundations, charities, sovereign wealth funds, corporations, official institutions, and banks.
NYSE:BLK traded up $9.24 on Wednesday, hitting $924.21. The stock had a trading volume of 167,936 shares, compared to its average volume of 684,774. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.45. BlackRock has a 52 week low of $752.30 and a 52 week high of $1,084.22. The business's fifty day moving average is $915.48 and its 200 day moving average is $979.95. The company has a market cap of $143.49 billion, a PE ratio of 22.00, a P/E/G ratio of 1.90 and a beta of 1.41.
Read Our Latest Research Report on BLK
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
